Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market and Novo Nordisk has faced lower prescriptions of Wegovy than expected.
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Novo Nordisk Earnings Are Soon. It’s All About Weight-Loss Drug Sales.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. When Novo’s competitor Eli Lilly reported its earnings last week,
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced drug delivery technology.
New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity
Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in addition to weight loss. Read more here.
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
Key Takeaways Danish pharmaceutical giant Novo Nordisk is set to report earnings for the third quarter of 2024 on Wednesday morning.Sales of its popular weight-loss drugs Ozempic and Wegovy will be Novo investors' focus.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... Lilly last week reported a rare $1.5 billion sales ...
BioPharma Dive6d
Lilly shares fall as obesity drug sales miss forecasts
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...
This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking said that an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...
STAT11d
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.Most Read from Bloombe ...
Wall Street Journal6d
Eli Lilly’s Bad Quarter Doesn’t Change Long-Term Math on Obesity Bonanza
Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors. (Shelby Knowles/Bloomberg News) Eli Lilly had a bad ...
STAT6d
Eli Lilly hits rare stumble, as sales and earnings disappoint
Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...
Viking Therapeutics surges after presenting ‘promising’ obesity drug data
Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental ...
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Q3 earnings call that wholesalers decreased their ...
NBC Los Angeles1h
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...